辉瑞肺癌创新靶向药多泽润正式在华上市( 五 )

[1]多泽润(达可替尼片)说明书.[2] Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwidefor 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.[3] Herbst RS, et al. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-454.[4] Yang P, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452–462.[5] Castellanos E, et al. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(4):612-623.


推荐阅读